2015
Intravenous Fluids in Acute Decompensated Heart Failure
Bikdeli B, Strait KM, Dharmarajan K, Li SX, Mody P, Partovian C, Coca SG, Kim N, Horwitz LI, Testani JM, Krumholz HM. Intravenous Fluids in Acute Decompensated Heart Failure. JACC Heart Failure 2015, 3: 127-133. PMID: 25660836, PMCID: PMC4438991, DOI: 10.1016/j.jchf.2014.09.007.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCohort StudiesDatabases, FactualFemaleFluid TherapyHeart FailureHospital MortalityHospitalizationHumansInfusions, IntravenousIntensive Care UnitsIntubation, IntratrachealIsotonic SolutionsMaleMiddle AgedRenal Replacement TherapyRetrospective StudiesRinger's SolutionSaline Solution, HypertonicSodium Potassium Chloride Symporter InhibitorsUnited StatesYoung AdultConceptsAcute decompensated heart failureDecompensated heart failureHeart failureIntravenous fluidsRetrospective cohort studyCritical care admissionRenal replacement therapyDays of hospitalizationProportion of hospitalizationsHalf-normal salineWarrants further investigationOnly diureticsCare admissionHospital deathHospital outcomesCohort studyLoop diureticsPatient groupReplacement therapyWorse outcomesNormal salineInpatient careMedian volumePatientsHospitalization
2014
Use of Intravenous Diuretics on Day of Discharge in Adults Hospitalized for Heart Failure
Fazel R, Strait KM, Bikdeli B, Dharmarajan K, Krumholz HM. Use of Intravenous Diuretics on Day of Discharge in Adults Hospitalized for Heart Failure. Journal Of Cardiac Failure 2014, 20: 706-707. PMID: 24951932, PMCID: PMC4427892, DOI: 10.1016/j.cardfail.2014.06.354.Peer-Reviewed Original ResearchHospital Variation in Intravenous Inotrope Use for Patients Hospitalized With Heart Failure
Allen LA, Fonarow GC, Grau-Sepulveda MV, Hernandez AF, Peterson PN, Partovian C, Li SX, Heidenreich PA, Bhatt DL, Peterson ED, Krumholz HM. Hospital Variation in Intravenous Inotrope Use for Patients Hospitalized With Heart Failure. Circulation Heart Failure 2014, 7: 251-260. PMID: 24488983, PMCID: PMC5459367, DOI: 10.1161/circheartfailure.113.000761.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiotonic AgentsCross-Sectional StudiesDose-Response Relationship, DrugFemaleFollow-Up StudiesGuideline AdherenceHeart FailureHospital MortalityHospitalsHumansInfusions, IntravenousInpatientsLength of StayMaleOutcome Assessment, Health CarePractice Patterns, Physicians'RegistriesRetrospective StudiesSurvival RateUnited StatesConceptsInotrope useHeart failureInotropic therapyInotropic agentsGuidelines-Heart Failure registryIntravenous inotropic agentsIntravenous inotropic therapyRisk-standardized ratesUse of inotropesHeart failure hospitalizationHospital-level ratesRandom hospital effectsFailure hospitalizationClinical characteristicsHospital factorsInpatient mortalityClinical factorsClinical outcomesHospital variationHospital characteristicsHospital effectsPatientsUS hospitalsHospitalStudy period
2013
Contraindicated Initiation of β-Blocker Therapy in Patients Hospitalized for Heart Failure
Dharmarajan K, Masoudi FA, Spertus JA, Li SX, Krumholz HM. Contraindicated Initiation of β-Blocker Therapy in Patients Hospitalized for Heart Failure. JAMA Internal Medicine 2013, 173: 1547-1549. PMID: 23797379, PMCID: PMC4043342, DOI: 10.1001/jamainternmed.2013.7717.Peer-Reviewed Original Research
1998
Use and Effectiveness of Intravenous Heparin Therapy for Treatment of Acute Myocardial Infarction in the Elderly
Krumholz H, Hennen J, Ridker P, Murillo J, Wang Y, Vaccarino V, Ellerbeck E, Radford M. Use and Effectiveness of Intravenous Heparin Therapy for Treatment of Acute Myocardial Infarction in the Elderly. Journal Of The American College Of Cardiology 1998, 31: 973-979. PMID: 9561996, DOI: 10.1016/s0735-1097(98)00022-9.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionIntravenous heparin therapyIntravenous heparinMyocardial infarctionHeparin therapyMortality rateFull-dose intravenous heparinRetrospective cohort studyHospital medical recordsUse of heparinReperfusion strategyCohort studyElderly patientsMedical recordsBaseline differencesObservational studyMedicare beneficiariesInfarctionTherapeutic effectivenessPatientsTreatment factorsHeparinContraindicationsTreatmentTherapy